High Dose Intravitreal Bevacizumab for Refractory Pigment Epithelial Detachment in Age-related Macular Degeneration
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose: Intravitreal anti-vascular endothelial growth factor (anti-VEGF) is the first choice of treatment forage-related macular degeneration. However, quite a few eyes treated using conventional dose anti-VEGF(CDAV) have persistent pigment epithelial detachment (PED) on optical coherence tomography. This studyinvestigated the efficacy and safety of high dose anti-VEGF (HDAV) for refractory PED. Methods: In this retrospective study, 31 eyes of neovascular age-related macular degeneration patients withpersistent PED findings despite six or more intravitreal injections of CDAV (bevacizumab 1.25 mg or ranibizumab2.5 mg) were analyzed. Changes in visual outcome, central foveal thickness, and PED height werecompared before and after HDAV (bevacizumab 5.0 mg) for these refractory PED cases. Results: The mean age of patients was 67.7 years. The number of CDAV injections was 12.1. The number ofHDAV injections was 3.39. Best-corrected visual acuity in logarithm of the minimum angle of resolution beforeand after HDAV was 0.49 and 0.41 (p < 0.001), respectively. Central foveal thickness before and afterHDAV was 330.06 and 311.10 μm (p = 0.125), respectively. PED height before and after HDAV was 230.28 and204.07 μm (p = 0.014), respectively. There were no serious adverse reactions in all the eyes. Conclusions: Increasing the dose of bevacizumab in refractory PED may be a possible treatment option.
Abstract
Purpose: Intravitreal anti-vascular endothelial growth factor (anti-VEGF) is the first choice of treatment forage-related macular degeneration. However, quite a few eyes treated using conventional dose anti-VEGF(CDAV) have persistent pigment epithelial detachment (PED) on optical coherence tomography. This studyinvestigated the efficacy and safety of high dose anti-VEGF (HDAV) for refractory PED. Methods: In this retrospective study, 31 eyes of neovascular age-related macular degeneration patients withpersistent PED findings despite six or more intravitreal injections of CDAV (bevacizumab 1.25 mg or ranibizumab2.5 mg) were analyzed. Changes in visual outcome, central foveal thickness, and PED height werecompared before and after HDAV (bevacizumab 5.0 mg) for these refractory PED cases. Results: The mean age of patients was 67.7 years. The number of CDAV injections was 12.1. The number ofHDAV injections was 3.39. Best-corrected visual acuity in logarithm of the minimum angle of resolution beforeand after HDAV was 0.49 and 0.41 (p < 0.001), respectively. Central foveal thickness before and afterHDAV was 330.06 and 311.10 μm (p = 0.125), respectively. PED height before and after HDAV was 230.28 and204.07 μm (p = 0.014), respectively. There were no serious adverse reactions in all the eyes. Conclusions: Increasing the dose of bevacizumab in refractory PED may be a possible treatment option.
참고문헌 (32)
- Klein R, "The epidemiology of age-related macular degeneration", Am J Ophthalmol, 137, pp.486~495 (2004)
- Bressler NM, "Potential public health impact of Age-Related Eye Disease Study results:AREDS report no. 11", Arch Ophthalmol, 121, pp.1621~1624 (2003)
- Ferris FL 3rd, "Age-related macular degeneration and blindness due to neovascular maculopathy", Arch Ophthalmol, 102, pp.1640~1642 (1984)
- Amin R, "Growth factor localization in choroidal neovascular membranes of age-related macular degeneration", Invest Ophthalmol Vis Sci, 35, pp.3178~3188 (1994)
- Kliffen M, "Increased expression of angiogenic growth factors in age-related maculopathy", Br J Ophthalmol, 81, pp.154~162 (1997)
- Avery RL, "Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration", Ophthalmology, 113, pp.363~372 (2006)
- Fung AE, "An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration", Am J Ophthalmol, 143, pp.566~583 (2007)
- Chan CK, "Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration", Retina, 27, pp.541~551 (2007)
- CATT Research Group, "Ranibizumab and bevacizumab for neovascular age-related macular degeneration", N Engl J Med, 364, pp.1897~1908 (2011)
- Brown DM, "Ranibizumab versus verteporfin for neovascular age-related macular degeneration", N Engl J Med, 355, pp.1432~1444 (2006)
- Rosenfeld PJ, "Ranibizumab for neovascular age-related macular degeneration", N Engl J Med, 355, pp.1419~1431 (2006)
- Gass JD, "Serous retinal pigment epithelial detachment with a notch: a sign of occult choroidal neovascularization", Retina, 4, pp.205~220 (1984)
- Gass JD, "Pathogenesis of tears of the retinal pigment epithelium", Br J Ophthalmol, 68, pp.513~519 (1984)
- Brown DM, "Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study", Ophthalmology, 116, pp.57~65 (2009)
- Gaudreault J, "Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration", Invest Ophthalmol Vis Sci, 46, pp.726~733 (2005)
- Pauleikhoff D, "Pigment epithelial detachment in the elderly: clinical differentiation, natural course and pathogenetic implications", Graefes Arch Clin Exp Ophthalmol, 240, pp.533~538 (2002)
- Casswell AG, "Retinal pigment epithelial detachments in the elderly: classification and outcome", Br J Ophthalmol, 69, pp.397~403 (1985)
- Inoue M, "Variable response of vascularized pigment epithelial detachments to ranibizumab based on lesion subtypes, including polypoidal choroidal vasculopathy", Retina, 33, pp.990~997 (2013)
- Parodi MB, "Intravitreal ranibizumab for pigment epithelium detachment with subfoveal occult choroidal neovascularization: a prospective 24-month case series", Am J Ophthalmol, 155, pp.103~108 (2013)
- Bolz M, "Effect of systemic bevacizumab therapy on retinal pigment epithelial detachment", Br J Ophthalmol, 91, pp.785~789 (2007)
- Chen E, "Intravitreal bevacizumab for refractory pigment epithelial detachment with occult choroidal neovascularization in age-related macular degeneration", Retina, 27, pp.445~450 (2007)
- Ach T, "Intravitreal bevacizumab in vascular pigment epithelium detachment as a result of subfoveal occult choroidal neovascularization in age-related macular degeneration", Retina, 30, pp.1420~1425 (2010)
- Modarres M, "Intravitreal injection of 2.5 mg versus 1.25 mg bevacizumab (Avastin) for treatment of CNV associated with AMD", Retina, 29, pp.319~324 (2009)
- Wu L, "Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up", Retina, 28, pp.212~219 (2008)
- Busbee BG, "Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration", Ophthalmology, 120, pp.1046~1056 (2013)
- Costa RA, "Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study", Invest Ophthalmol Vis Sci, 47, pp.4569~4578 (2006)
- Chan CK, "High-dose ranibizumab therapy for vascularized pigment epithelial detachment", Eye (Lond), 26, pp.882~885 (2012)
- Brown DM, "Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point", Ophthalmology, 120, pp.349~354 (2013)
- Rosenfeld PJ, "Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration", Ophthalmology, 113, pp.623.e1~ (2006)
- Manzano RP, "Testing intravitreal toxicity of bevacizumab (Avastin)", Retina, 26, pp.257~261 (2006)
- Feiner L, "Safety of intravitreal injection of bevacizumab in rabbit eyes", Retina, 26, pp.882~888 (2006)
- Shahar J, "Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin)", Retina, 26, pp.262~269 (2006)